Medifast (FRA:MDF) Stock Based Compensation: €6.5 Mil (TTM As of Mar. 2026)


FRA:MDF Medifast Inc FRA:MDF
68 GF Score
Price €9.49
GF Value €6.99
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medifast Stock Based Compensation?

Medifast FRA:MDF +4.52% 68 Stock Based Compensation is €6.5 Mil as of Mar. 2026. GuruFocus rates FRA:MDF with a GF Score™ of 68/100 and a GF Value™ of €6.99 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Medifast's Stock Based Compensation for the three months ended in Mar. 2026 was €1.6 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €6.5 Mil.

Medifast Stock Based Compensation Related Terms

Medifast Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Medifast's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medifast Stock Based Compensation Chart

Medifast Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.76 10.43 7.51 7.03 6.52

Medifast Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.79 2.28 0.78 1.86 1.64
FRA:MDF
68GF Score
Medifast Inc FRA:MDF
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medifast Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.5 Mil.

What does a Stock Based Compensation of €6.5 Mil mean?
Medifast (FRA:MDF) has a Stock Based Compensation of €6.5 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Medifast and its competitors.
Is Medifast's Stock Based Compensation too high?
Medifast's current Stock Based Compensation is €6.5 Mil. Overall, Medifast has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medifast's Stock Based Compensation compare to RGS and EVTK?
Medifast's Stock Based Compensation of €6.5 Mil can be compared against companies in the Personal Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Personal Services company?
A good Stock Based Compensation depends on the Personal Services industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Medifast and its competitors. Medifast's current Stock Based Compensation is €6.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medifast stock overvalued right now?
Based on GuruFocus' analysis, Medifast (FRA:MDF) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.99, compared to a current price of €9.49 — trading 35.8% above its estimated fair value. The current Stock Based Compensation is €6.5 Mil. Medifast's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Medifast (FRA:MDF), the current Stock Based Compensation is €6.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medifast (FRA:MDF) Overvalued in 2026?

Based on GuruFocus' analysis, Medifast stock appears to be overvalued. The current stock price of €9.49 is trading 35.8% above its estimated GF Value™ of €6.99. GuruFocus considers Medifast to be Significantly Overvalued.

Key valuation signals for FRA:MDF:

  • Stock Based Compensation: €6.5 Mil
  • GF Value™: €6.99 vs. price of €9.49 (35.8% above fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the FRA:MDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medifast Business Description

Other Exchanges MED:USA0K05:UKMDF:Germany
Address 100 International Drive, Baltimore, MD, USA, 21202
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
68GF Score

Get the complete analysis for FRA:MDF

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.49
Price
€6.99
GF Value